Exelixis company profile
Company profile
Exelixis has 1,077 employees and is headquartered in Alameda, United States.
Incorporated in 1994 and based in Alameda, California, Exelixis offers medicines for cancers that are difficult to treat. Its marketed products include CABOMETYX, used for advanced renal cell carcinoma after prior anti-angiogenic therapy, COMETRIQ for progressive and metastatic medullary thyroid cancer, and COTELLIC, used in combination for certain forms of advanced melanoma. MINNEBRO is offered for hypertension in Japan. Its pipeline includes zanzalintinib and several antibody-drug conjugates, and the company has research collaborations and license agreements with Takeda, Roche, Genentech, Bristol-Myers Squibb and Daiichi Sankyo.
In the fiscal year ended January 2, 2026, revenue was $2.3 billion, up 7.0% from the prior year, and net income reached $782.6 million. Revenue by region was 92.3% from the United States, 6.6% from Europe and 1.1% from Japan. The company had 1,077 employees.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 1851 Harbor Bay Parkway, 94502, Alameda
- Employees
- 1,077
- Chief executive
- Michael Morrissey
- Founded
- 1994
- Fiscal year
- January - December
- Listing
- EXEL · NASDAQ
- Currency
- USD
- ISIN
- US30161Q1040
- Website
- exelixis.com
Exelixis and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ExelixisEXEL | United States | $16.84B | 1,077 | 40.2% | 20.7 |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| Jazz PharmaceuticalsJAZZ | United States | $15.5B | 2,890 | 27.4% | 71.5 |
| BridgeBio PharmaBBIO | United States | $15.25B | 1,081 | -37.3% | — |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
